In August of 2014, Sherry Pollex became a part of this incredible, strong, inspirational and ever beautiful community of ovarian cancer survivors. OCRA first got to know Sherry when she was first diagnosed. We knew right away that Sherry was a special person, when her first question was, “How can I help save other women … Continued
Later this week, we’ll be sending out a request for you to take Action to help protect ovarian cancer research funding at the Department of Defense. The Ovarian Cancer Research Program (OCRP) is part of the Congressionally Directed Medical Research Program in the Department of Defense (DoD), and funds innovative and cutting edge ovarian cancer … Continued
FOR IMMEDIATE RELEASE May 17, 2016 Lisa Mauti lmauti@ocrfa.org 202-517-6410 Supreme Court Returns Zubik v. Burwell to Lower Courts to Resolve Access to Cost-Free Contraceptive Services to Women “We urge the lower courts to move quickly and to consider the impact of their decision on the future of women’s preventative healthcare, especially as a … Continued
Check out our webinar by Chad Ramsey, VP of Policy, and Alison Silberman, Director of Field Engagement, to learn about OCRFA’s legislative efforts in 2016. You’ll hear about the issues we are working on and learn about ways you can get involved to help make a difference for women with ovarian cancer. Watch more webinars.
In his final State of the Union address, President Obama announced a national initiative to find a cure to cancer. Details are beginning to emerge about the plan and the President has requested $1 Billion in new funding over the next two years to boost the effort. As Congress begins to consider annual appropriations legislation, … Continued
Last week the United States Preventive Services Task Force (USPSTF) released its fifth report to Congress highlighting women’s health as a high priority gap in clinical preventative services. Recognizing the reproductive and biologic differences in women, as well as such external factors as home and work environments and economic and educational resources, the USPSTF has … Continued
November 18, 2015 Contact: Lisa Mauti lmauti@ovariancancer.org Public health evidence points to need for FDA regulation of laboratory developed tests “The consequences of inaccurate test results, such as false positives, can result in the unnecessary removal of a woman’s ovaries. It is critical that patients know their test results can be trusted.” Washington, DC — … Continued
Washington, DC — On November 17th, the Food and Drug Administration (FDA) released a report: The Public Health Evidence for FDA Oversight of Laboratory Developed Tests: 20 Case Studies, that outlines the harm that not regulating laboratory developed tests (LDTs) can cause to patients and to the economy. Included in the report were two case studies about … Continued
For Immediate ReleaseSeptember 23, 2015 New Ovarian Cancer National Alliance research finds state lawmakers have power to dramatically improve access to ovarian cancer care and outcomes for the 21,000 women diagnosed each year WASHINGTON, D.C. — Today, the Ovarian Cancer National Alliance (OCNA) released groundbreaking new data in its report “50 States of Teal: Ovarian … Continued
For Immediate ReleaseSeptember 28, 2015 Representatives Sean Duffy (R-WI) and Rosa DeLauro (D-CT) to launch Congressional Ovarian Cancer Caucus at Rally on Tuesday Representatives Sean Duffy (R-WI) and Rosa DeLauro (D-CT) to launch Congressional Ovarian Cancer Caucus at Rally on Tuesday WASHINGTON, D.C. — Tomorrow, Representatives Sean Duffy and Rosa DeLauro, who have each been … Continued
In January’s State of the Union Address, President Obama ushered in an exciting phase in new medical research by introducing the Precision Medicine Initiative (PMI). This initiative will expand our understanding of personalized medicine, when doctors pick treatments to suit individual patients rather than the ‘one-size-fits-all’ approach. Since January, the President’s advisers have begun to … Continued
By Annie Ellis: On September 3, 2015, Ovarian cancer survivors and FDA Patient Representatives Peg Ford, Susan Leighton and Annie Ellis were invited to provide the patient perspective at the recent Ovarian Cancer Endpoints Workshop hosted by the Food and Drug Administration (FDA). This meeting was co-sponsored by the Society of Gynecologic Oncology (SGO), the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO). Click plus sign to read more.
Get email updates about research news, action alerts, and ways to join the fight.
